
NON-SMALL CELL LUNG CANCER (NSCLC)

You Deserve Complete Answers



CARIS® LIFE SCIENCES

What is Biomarker Testing?

Cancer cells have developed "errors" called mutations that lead to abnormal growth and spread. Biomarker testing identifies mutations and helps doctors learn more about the unique biology of **your** individual cancer.

Why This Matters



Every cancer has a story. Biomarker testing helps tell that story.

Think of your cancer like a book.

Some tests read a few pages.

Other tests read more of the story.

Because cancer errors can hide in different places, different types of tests are needed. No single testing method finds every type of biomarker, which can lead to potentially missing information important to your care.

The more information your care team has, the more personalized treatment decisions can be.

Comprehensive Biomarker Testing May Help Identify:

- **What is driving your cancer's growth**
- **Additional potential treatment options**
- **Open clinical trial opportunities**



Some Tests Read Part of the Story



Comprehensive Biomarker Testing Reads the Full Story

Get a More Complete Picture

Many labs test a selection of biomarkers, but not all labs offer comprehensive biomarker testing. For more information, visit CarisLifeSciences.com/Patients.

Ask whether your testing includes the following:	
DNA Testing	✓
RNA Testing	✓
Protein Testing	✓
All NCCN-Recommended NSCLC Biomarkers	✓
Tissue and Blood Testing Options	✓
All Results Up Front to Help Guide Care	✓

Genetic testing looks for inherited DNA errors that can run in families and affect disease risk, while genomic testing analyzes tumors, primarily to find treatment targets. These errors can occur in any part of your DNA or RNA, so comprehensive testing — analyzing all DNA and RNA, versus just a small subset — is helpful for guiding personalized diagnosis and treatment.

Caris believes every patient deserves access to the best insights available. We maintain in-network coverage with most major commercial payers; financial assistance also is available for qualifying patients.

Two Patients, Two Paths.

Meet Emily*



Soon after diagnosing her Stage IV NSCLC, Emily's doctor ordered comprehensive biomarker testing, which simultaneously provided insights from DNA, RNA and protein testing.

What Emily Learned:

- **Specific insights about her cancer**
- **Information about potential treatment options**
- **What questions to discuss with her doctor**



Meet David*

David had biomarker testing earlier in his care but later learned that additional testing could provide more information. His doctor reviewed whether more testing might be helpful.

What David Learned:

- **Cancer care can evolve over time**
- **Different tests may provide new information**
- **It's always okay to ask whether additional testing may help**

There is No Single "Right" Path

Patients may receive testing at different times based on their personal situation, tissue availability, prior testing, individual treatment response and physician recommendations. Talk with your healthcare team about whether additional biomarker testing may be beneficial for you.

**Not real patients; for illustrative purposes only*

Additional Support and Resources for Patients

Scan to learn more, or visit CarisLifeSciences.com/Patients for more information on biomarker testing, including:

- How to find the right test for your situation
- Helpful questions to ask your doctor
- Success stories from patients like you
- Insurance coverage and financial assistance

Patient Advocacy Organizations

GO2 FOR LUNG CANCER

LUNGEVITY
Transforming Lung Cancer

ALK+

LCFA
Lung Cancer Foundation of America

LUNGCAN

You Deserve Clear Information

Talk with your healthcare team about whether your testing is providing the most complete picture possible.

Scan to learn more, or visit CarisLifeSciences.com/Patients.

CARIS® LIFE SCIENCES

Where Molecular Science Meets Artificial Intelligence.

©2026 Caris MPI, Inc. All rights reserved. MAT-NP-000365 10 SEP 2026